Significance of change in serum bilirubin in predicting left ventricular reverse remodeling and outcomes in heart failure patients with cardiac resynchronization therapy

Hosoda, Junya; Ishikawa, Toshiyuki; Matsumoto, Katsumi; Iguchi, Kenta; Matsushita, Hirooki; Ogino, Yutaka; Taguchi, Yuka; Sugano, Teruyasu; Ishigami, Tomoaki; Kimura, Kazuo; Tamura, Kouichi

doi:10.1016/j.jjcc.2017.04.001

Cited by 10 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hosoda et al (Ref. 35; Table 1) also demonstrated poor prognoses in patients with heart failure with elevated baseline total bilirubin levels before cardiac resynchronization therapy. Furthermore, when 69 patients were divided into groups with increasing or decreasing bilirubin concentrations~5 mo after resynchronization, patients with decreasing total bilirubin levels demonstrated improved end-systolic/diastolic diameters and ejection fraction, with fewer instances of cardiac death and rehospitalization for heart failure over a 39 mo followup.…”

Section: Protection Of the Myocardium From Acute Ischemia-reperfusion Injurymentioning

confidence: 94%

Bilirubin acts as a multipotent guardian of cardiovascular integrity: more than just a radical idea

Bulmer

Bakrania

Toit

et al. 2018

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

Bilirubin, a potentially toxic catabolite of heme and indicator of hepatobiliary insufficiency, exhibits potent cardiac and vascular protective properties. Individuals with Gilbert's syndrome (GS) may experience hyperbilirubinemia in response to stressors including reduced hepatic bilirubin excretion/increased red blood cell breakdown, with individuals usually informed by their clinician that their condition is of little consequence. However, GS appears to protect from all-cause mortality, with progressively elevated total bilirubin associated with protection from ischemic heart and chronic obstructive pulmonary diseases. Bilirubin may protect against these diseases and associated mortality by reducing circulating cholesterol, oxidative lipid/protein modifications, and blood pressure. In addition, bilirubin inhibits platelet activation and protects the heart from ischemia-reperfusion injury. These effects attenuate multiple stages of the atherosclerotic process in addition to protecting the heart during resultant ischemic stress, likely underpinning the profound reduction in cardiovascular mortality in hyperbilirubinemic GS. This review outlines our current knowledge of and uses for bilirubin in clinical medicine and summarizes recent progress in revealing the physiological importance of this poorly understood molecule. We believe that this review will be of significant interest to clinicians, medical researchers, and individuals who have GS.

show abstract

Section: Protection Of the Myocardium From Acute Ischemia-reperfusion Injurymentioning

confidence: 94%

Bilirubin acts as a multipotent guardian of cardiovascular integrity: more than just a radical idea

Bulmer

Bakrania

Toit

et al. 2018

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

show abstract

“…STB levels are associated with a high thrombus burden in STEMI patients [ 28 ]. STB could be elevated in HF patients, and reduced STB could reflect improved end-systolic/diastolic diameters and ejection fraction (EF) after resynchronization therapy [ 29 ]. Elevated bilirubin is also an independent predictor for hypertensive patients [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Elevated Serum Total Bilirubin Might Indicate Poor Coronary Conditions for Unstable Angina Pectoris Patients beyond as a Cardiovascular Protector

Liang,

Zhang,

Liang

2023

Cardiovascular Therapeutics

View full text Add to dashboard Cite

Backgrounds. Serum total bilirubin (STB) is recently more regarded as an antioxidant with vascular protective effects. However, we noticed that elevated STB appeared in unstable angina pectoris (UAP) patients with diffused coronary lesions. We aimed to explore STB’s roles in UAP patients, which have not been reported by articles. Methods and Results. 1120 UAP patients were retrospectively screened, and 296 patients were finally enrolled. They were grouped by Canadian Cardiovascular Society (CCS) angina grades. The synergy between PCI with TAXUS stent and cardiac surgery score (SYNTAX score) and corrected thrombolysis in myocardial infarction flow count (CTFC) were adopted to profile coronary features. The results showed that STB, mean platelet volume (MPV), hs-CRP, fasting blood glucose (FBG), red blood cell width (RDW), and CTFC elevated significantly in the CCS high-risk group. STB ( B = 0.59 , 95% CI: 0.39-0.74, P < 0.01 ) and MPV ( B = 0.86 , 95% CI: 0.42-1.31, P < 0.01 ) could indicate SYNTAX score changes for these patients. STB (≥21.7 μmol/L) could even indicate a coronary slow flow condition (AUC: 0.88, 95% CI: 0.84-0.93, P < 0.01 ). Moreover, UAP patients with elevated STB had a lower event-free survival rate by the Kaplan-Meier curve. STB ≥21.7 μmol/L could reflect a poor coronary flow status and indicate 1-year poor outcomes for these patients (HR: 2.01, 95% CI: 1.06-3.84, P < 0.01 ). Conclusion. Elevated STB in UAP patients has a close relationship with changes in SYNTAX score. STB (over 21.7 μmol/L) could even indicate a coronary slow flow condition and poor outcomes for the UAP patients.

show abstract

“…Hence, the proper discretion has to be shown in interpreting the data of blood tests. Intriguingly, it has also been reported that a decreased ratio in serum bilirubin could predict LV reverse remodeling and outcomes in HF patients with CRT [21]. Dutta et al demonstrated that administration of b-3 blocker attenuates peripheral monocytosis and infiltration of monocytes into myocytes in mice with myocardial infarction [3].…”

Section: Discussionmentioning

confidence: 99%

Association between the baseline peripheral blood monocyte counts, the size of spleen, and the response to cardiac resynchronization therapy

Fujinami

Kondo

Yufu

et al. 2018

Journal of Cardiology

View full text Add to dashboard Cite

show abstract

Significance of change in serum bilirubin in predicting left ventricular reverse remodeling and outcomes in heart failure patients with cardiac resynchronization therapy

Abstract: The change in serum bilirubin is useful for assessment of left ventricular reverse remodeling and prediction of outcomes in heart failure patients with CRT.

Cited by 10 publications

References 24 publications

Bilirubin acts as a multipotent guardian of cardiovascular integrity: more than just a radical idea

Bilirubin acts as a multipotent guardian of cardiovascular integrity: more than just a radical idea

Elevated Serum Total Bilirubin Might Indicate Poor Coronary Conditions for Unstable Angina Pectoris Patients beyond as a Cardiovascular Protector

Association between the baseline peripheral blood monocyte counts, the size of spleen, and the response to cardiac resynchronization therapy

Contact Info

Product

Resources

About